Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMed Pharmaceuticals has started dosing patients in a Phase Ia clinical trial of its anti-DLL4/VEGF bispecific antibody (OMP-305B83), which is designed to have both anti-cancer stem cell and anti-angiogenic activity.
Subscribe to our email newsletter
The company said that patients with advanced refractory solid tumors are being enrolled in the single-agent Phase Ia open-label dose-escalation trial.
Currently, being conducted at four sites in the US, the trial will evaluate the safety, pharmacokinetics, pharmacodynamics and initial evidence of efficacy of the anti-DLL4/VEGF bispecific antibody.
OncoMed chairman and chief executive officer Paul Hastings said: "This is the sixth novel product candidate discovered by OncoMed researchers and the second product from our multi-billion dollar collaboration with Celgene to be advanced to the clinic by our development team.
"This antibody leverages the clinical experience gained with our anti-DLL4 antibody, demcizumab, which has demonstrated encouraging early signs of clinical activity in Phase Ib clinical trials."
The bispecific antibody was discovered using the company’s MAbTrap antibody display technology, which helps in the rapid identification of monoclonal antibodies that bind targets with high affinity and specificity.
The antibody is the first program based on the company’s BiMAb bispecific platform technology, which allows bispecific antibodies with traditional antibody shape, to enter clinical testing.
In preclinical studies, its anti-DLL4/VEGF bispecific antibody showed robust in vivo anti-tumor efficacy across a range of solid tumor xenografts, including colon, lung and pancreatic cancers, among others.